British Journal of Pharmacology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 21, 2024
Several RNA-type molecules have reached the market recently, and use of noncoding RNAs for therapeutic purposes is a booming field pharmacology drug development (Caporali et al., 2024; Dzau & Hodgkinson, Nemeth Parhiz Tang Khvorova, 2024). Leading authors provide joint effort to discuss recent progress future perspectives on this emerging pharmacology. The work presented in Themed Issue mainly stems from networking activities within three Cooperation Science Technology (COST) Actions, funded by European Commission. Most articles included are members these COST Actions. Cardioprotection Action 2017–2022 had objective facilitate translation novel cardioprotective therapies clinic (www.cardioprotection.eu) (Ferdinandy 2023; Hausenloy Heusch, 2019). CardioRNA 2018–2023 aimed catalyse collaborative research cardiovascular RNA (www.cardiorna.eu) (Badimon Devaux, 2020). AtheroNET 2022–2026 aims delve into potential multiomics better understand treat atherosclerotic disease (www.atheronet.eu) (Sopic, Kararigas, 2023). On 7 October 2020, Royal Swedish Academy Sciences awarded Nobel Prize Chemistry Professors Doudna Charpentier their breakthrough CRISPR technology (N. P. O. A., 2023a). Since then, extensive has shown very promising results modern medicine (Pacesa 2 2023, Physiology or Medicine was Karikó Weissman ground-breaking mRNA modification 2023b). One year later, 7th, 2024, Ambros Ruvkun microRNAs These prizes reflect keen interest research. Recent technical innovations boosted mRNA-based therapies, including quick vaccines against SARS-CoV2. In regard, usefulness extends beyond diagnosis treatment. Both coding possess high biomarker (Devaux 2015; Winkle 2021). Developing "theranostics" ("theragnostics") approaches based diagnose, monitor progression holds significant improve personalized healthcare Vilne, especially represent actionable biomarkers, useful diagnosis, prediction monitoring of, example, ischaemic heart Using both early accurate disease-modifying may help advance clinical outcomes (theranostics concept; Figure 1). We believe that therapeutics patients suffering but also any other where homeostasis dysregulated. value as drugs targets been thoroughly discussed illustrated invited review British Journal Pharmacology. A Spanish team led Dr. David de Gonzalo-Calvo emphasizes mitigate persistent pulmonary complications after COVID-19 (García-Hidalgo Dr Paola Di Pietro colleagues report capacity miRNA-1-3p predict severity hospitalized (Di Yvan Devaux Luxembourg reviews current knowledge atherosclerosis (Sopić 2024), while Drs. Gerhild Euler Mariana Parahuleva focus monocytic treatment (Euler Parahuleva, Andrew Baker covers vascular smooth muscle cell dysfunction (Brown Aida Collado co-workers study miR-210 diabetes-associated endothelial (Collado An international focusses circular role cardiac remodelling (Bibi Exploitation cancer therapy-related cardiotoxicity covered Gabriela Kuster her Switzerland (Bernasconi Kuster, Hungarian Prof. Peter Ferdinandy discusses avoid off-target effects small (Bereczki 2024) reports two translational studies aiming test miR-125b* murine model acute myocardial infarction (Szabados miR-450a pig without with intervention, is, preconditioning (Nagy Finally, Italian group Serena Zacchigna compares currently available discovery platforms (Ciucci Overall, gathers original diverse groups supporting pharmacological agents population health. Editors call accelerated field. YD drafted manuscript; SZ RS reviewed edited manuscript. This Editorial upon CA16225 (www.cardioprotection.eu/), CA17129 CA21153 (European Technology; www.cost.eu). Y. D. filled patents related diagnostic member Scientific Advisory Board molecular company Firalis SA.
Language: Английский
